Jiangsu Nhwa Pharmaceutical: 2024 revenue and net profit rose double digits, with strong CNS drug and digital health growth

About this update from Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

Jiangsu Nhwa Pharmaceutical posted 13% revenue and 10% net profit growth in 2024, driven by CNS drug leadership and increased R&D, while expanding digital health and launching new products. Dividend payout ratio reached 31.99%.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A